Data from a retrospective observational study conducted using the electronic health record at the Cleveland Clinic, shows that real-world weight loss can be associated with a reduced risk of obesity-related cancers.
The findings were presented as a Late-Breaking Poster at the 84th Scientific Sessions of the American Diabetes Association (ADA) in Orlando, FL.
Overall, 78% of people with diabetes have clinical obesity. Obesity is linked to higher risks of at least 13 types of cancer due to excess estrogen and elevated insulin, including breast, kidney, ovary, liver, and pancreatic cancer.
There is an increased need to further understand the association between diabetes, obesity, and cancer and corresponding treatments.
The study included a total of 172 patients including 100,143 in the control arm and 5,329 cases.
The median body mass index (BMI at censoring (kg/m2.) was 34.2 for cases and 34.5 for controls, which are considered to have obesity according to the Centers for Disease Control and Prevention (CDC).
The association between the percentage change in body mass index (BMI) with three, five, and 10-year intervals prior to cancer diagnosis (for cases) versus controls for each cancer endpoint was assessed using logistic regression models.
The primary endpoint of this study shows 13 obesity-related cancers found.
The secondary endpoint of this study was highlighted with the occurrence of 16 other types of cancer including melanoma and other skin malignancies as well as cancers related to the urinary tract, hematopoietic and lymphoid tissues, respiratory and intrathoracic organs, male genital organs, female genital organs, eye, brain and other parts of the central nervous system, and digestive organs.
In this study, data shows that real-world weight loss is associated with a reduced risk of obesity-related cancers.
The results show a reduced risk of developing obesity-related cancers with weight loss at three years (OR 0.99, 95%CI [0.984, 0.996]) and five years (OR 0.989,95% CI [0.983-0.995]), and for other types of cancer for all time intervals (ORs<1, P <0.001).
The risk was reduced for renal cell carcinoma (three years), multiple myeloma (10 years), and endometrial cancer (three and five years) among primary cancer endpoints (P<0.05).
“This study reinforces how crucial it is to treat obesity as a chronic disease,” said Kenda Alkwatli, MD, Clinical Fellow at Cleveland Clinic, and author of the study. “We are hopeful that these results can help us better understand how we can use weight loss to address comorbidities including cancer in patients with obesity.”
This study is an example of why more research is needed to determine whether cancer risk is influenced by the amount, rate, and method of weight loss. Future studies will focus on and test to see if specific anti-obesity medications can reduce cancer risk.
